Resumen
The RET kinase receptor is a target of mutations in neural crest tumors, including pheochromocytomas, and of oncogenic fusions in epithelial cancers. We report a RET::GRB2 fusion in a pheochromocytoma in which RET, functioning as the upstream partner, retains its kinase domain but loses critical C-terminal motifs and is fused to GRB2, a physiological RET interacting protein. RET::GRB2 is an oncogenic driver that leads to constitutive, ligand-independent RET signaling; has transforming capability dependent on RET catalytic function; and is sensitive to RET inhibitors. These observations highlight a new driver event in pheochromocytomas potentially amenable for RET-driven therapy.
| Idioma original | English (US) |
|---|---|
| Número de artículo | 100686 |
| Publicación | Cell Reports Medicine |
| Volumen | 3 |
| N.º | 7 |
| DOI | |
| Estado | Published - jul 19 2022 |
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
Huella
Profundice en los temas de investigación de 'A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions'. En conjunto forman una huella única.Citar esto
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS